Losartan Potassium Tablet, Film Coated
Product Images NDC 68071-5181

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68071-5181). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 5181 9)

Label for Losartan Potassium 100 mg tablets from NuCare Pharmaceuticals, Inc., shows a quantity of 90 tablets. It includes the NDC number 68071-5181-9 and denotes the product as prescription only (Rx Only). Manufacturing is attributed to Hetero Labs Limited in India, with storage information and warnings to keep out of reach of children.*

FDA Label Image

Losartanaddress1 (Losartanaddress1)

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over study months for Atenolol (dotted line) and Losartan potassium (solid line). The x-axis represents study months from 0 to 60, and the y-axis shows the percentage of patients up to 16%. An adjusted risk reduction of 13% with p=0.021 is noted.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a 66-month study period between Atenolol and Losartan Potassium. The graph shows a lower stroke incidence for Losartan Potassium, with a stated adjusted risk reduction of 25% (p=0.001). The x-axis represents study months, and the y-axis shows percentage of patients.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

Figure 3 displays a forest plot illustrating primary endpoint events within demographic subgroups, comparing Losartan Potassium and Atenolol event rates for Primary Composite and Stroke (Fatal/Non-Fatal) outcomes. The plot includes hazard ratios with 95% confidence intervals across various subgroups defined by age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD). Symbols represent hazard ratios proportional to sample sizes.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients with an event over time (months) between Losartan Potassium and placebo groups. The graph indicates risk reduction and a p-value, showing cumulative event percentages on the vertical axis up to 48 months.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure of Losartan Potassium, showing its molecular components including chlorine, hydroxyl, imidazole, benzene rings, and potassium ion. The structure reflects the arrangement of its atoms and bonds as part of the active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.